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Association Between LifetimeMarijuana Use
and Cognitive Function inMiddle Age
The Coronary Artery Risk Development in Young Adults
(CARDIA) Study
Reto Auer, MD, MAS; Eric Vittinghoff, PhD, MPH; Kristine Yaffe, MD; Arnaud Künzi, BA; Stefan G. Kertesz, MD, MSc;
Deborah A. Levine, MD, MPH; Emiliano Albanese, MD, PhD, MPH; Rachel A. Whitmer, PhD;
David R. Jacobs Jr, PhD; Stephen Sidney, MD; M. Maria Glymour, ScD, MS; Mark J. Pletcher, MD, MPH
IMPORTANCE Marijuana use is increasingly common in the United States. It is unclear whether
it has long-term effects onmemory and other domains of cognitive function.
OBJECTIVE To study the association between cumulative lifetime exposure to marijuana use
and cognitive performance in middle age.
DESIGN, SETTING, AND PARTICIPANTS Weused data from the Coronary Artery Risk
Development in Young Adults (CARDIA) study, a cohort of 5115 black andwhitemen and
women aged 18 to 30 years at baseline fromMarch 25, 1985, to June 7, 1986 (year 0), and
followed up over 25 years from June 7, 1986, to August 31, 2011, to estimate cumulative years of
exposure tomarijuana (1 year = 365 days ofmarijuana use) using repeatedmeasures and to
assess associationswith cognitive function at year 25. Linear regressionwas used to adjust for
demographic factors, cardiovascular risk factors, tobacco smoking, use of alcohol and illicit
drugs, physical activity, depression, and results of themirror star tracing test (ameasure of
cognitive function) at year 2. Data analysis was conducted from June 7, 1986, to August 31, 2011.
MAIN OUTCOMES ANDMEASURES Three domains of cognitive function were assessed at year
25 using the Rey Auditory Verbal Learning Test (verbal memory), the Digit Symbol
Substitution Test (processing speed), and the Stroop Interference Test (executive function).
RESULTS Among 3385 participants with cognitive functionmeasurements at the year 25 visit,
2852 (84.3%) reported past marijuana use, but only 392 (11.6%) continued to usemarijuana
into middle age. Current use of marijuana was associated with worse verbal memory and
processing speed; cumulative lifetime exposure was associated with worse performance in all
3 domains of cognitive function. After excluding current users and adjusting for potential
confounders, cumulative lifetime exposure to marijuana remained significantly associated
with worse verbal memory. For each 5 years of past exposure, verbal memory was 0.13
standardized units lower (95% CI, −0.24 to −0.02; P = .02), corresponding to a mean of 1 of 2
participants remembering 1 word fewer from a list of 15 words for every 5 years of use. After
adjustment, we found no associations with lower executive function (–0.03 [95% CI, −0.12 to
0.07]; P = .56) or processing speed (–0.04 [95% CI, −0.16 to 0.08]; P = .51).
CONCLUSIONS AND RELEVANCE Past exposure tomarijuana is associated with worse verbal
memory but does not appear to affect other domains of cognitive function.
JAMA Intern Med. 2016;176(3):352-361. doi:10.1001/jamainternmed.2015.7841
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M arijuana use is common among adolescents andyoungadults.Data fromtheUnitedStates in2012 in-dicate that among students in the 12th grade (aged
17-18years), 37%hadusedmarijuanawithin the last year, 23%
within the last 30 days, and 6.5% daily.1 If marijuana has sig-
nificant long-term adverse effects, use early in life may have
importantpublichealthconsequences.Long-termeffects from
marijuana use, however, can be difficult to detect.
Impaired cognitive function is an acute effect of mari-
juana use,2 and there is increasing evidence that such effects
may persist later in life.3-5 Heavy, long-term use of marijuana
hasbeenassociatedwith cognitive impairment, particularly in
learning and rememberingnew information.3,6 Evidence from
population-basedstudies,however, is scarce,andit remainsun-
clearwhether thereare long-termeffects from low-intensityor
occasionalmarijuana use earlier in life3 andwhether themag-
nitude and persistence of impairment depends on the dura-
tion of cannabis use or the age of exposure.4,5
With 25 years of repeated measurements of marijuana
exposure starting in early adulthood, the Coronary Artery
Risk Development in Young Adults (CARDIA) study provides
an opportunity to assess the long-term effects of marijuana
exposure among community-based adults. In year 25, CAR-
DIA measured cognitive performance using standardized
tests of verbal memory, processing speed, and executive
function. We used these measurements to study the associa-
tion between cumulative years of exposure to marijuana use
and cognitive performance inmiddle age among CARDIA par-
ticipants with marijuana exposures typical of the communi-
ties in which they live.
Methods
Study Design and Sample
TheCARDIA study is a population-based epidemiologic study
of 5115 adults aged 18 to 30years at baseline; these adultswere
followedup fromJune7, 1986, toAugust 31, 2011.7 Participants
were recruited fromMarch25, 1985, to June7, 1986,by random
selectionof telephonenumbers fromdesignated census tracts
inBirmingham,Alabama;Chicago, Illinois;Minneapolis,Min-
nesota; and by random selection from themembership list of
ahealthcareplan inOakland,California.Thesampling scheme
wasdesigned to achieve abalance at eachof the4 sites by race
(self-identified as black, notHispanic orwhite, notHispanic),
sex, educational level (high school degreeor less ormore than
high school), and age (18-24 years or 25-30 years). All partici-
pantsprovidedwritten informedconsent,with institutional re-
viewboardapproval ateach fieldcenter (UniversityofAlabama
atBirmingham,NorthwesternUniversity,UniversityofMinne-
sota, and Kaiser Permanente).
Marijuana Exposure: Current and Cumulative
Current marijuana use was assessed at each in-person
CARDIA visit (at baseline and after 2, 5, 7, 10, 15, 20, and 25
years of follow-up)using the following surveyquestion: “Dur-
ing the last 30 days, on how many days did you use mari-
juana?” Direct self-reported lifetime exposure was assessed
using the question, “About how many times in your lifetime
have you usedmarijuana?”We used current and lifetime use
to compute marijuana-years, with 1 year of exposure equiva-
lent to 365 days of marijuana use (eAppendix 1 in the
Supplement).8 We assumed that current use at each visit (ie,
the number of days of using marijuana during the month be-
foreeachvisit) reflected theaveragenumberofdaysofusedur-
ing the months before and after each visit. We estimated the
cumulative lifetime use by adding the total number of days
using marijuana during follow-up. We adjusted our estimate
upwardwheneverdirectlyself-reported lifetimeusewashigher
than our computed estimates.8
OutcomeMeasure
Cognitive function was assessed by trained and certified
CARDIA technicians who administered a battery of 3 cogni-
tive tests at theyear25visit.9TheReyAuditoryVerbalLearning
Test (RAVLT)mainly assessesverbalmemory through theabil-
ity tomemorizeandretrieve listsof 15words.TheRAVLTyields
3 separate scores; in themainanalysesweused thedelayed (25
minutes) free recall scoreonly (andused theother2 in sensitiv-
ityanalyses [eAppendix 1 in theSupplement]).10TheDigit Sym-
bolSubstitutionTestassessesvisualmotorspeed,executivefunc-
tion, sustainedattention,andworkingmemory;werefer to this
domainasprocessingspeed.11TheStroopInterferenceTestevalu-
ates theability toviewcomplexvisual stimuli andto respondto
1stimulusdimensionwhilesuppressingtheresponsetoanother
dimension;werefer tothisdomainasexecutive function.12,13The
resulting interferencescoreprovidesameasureofhowmuchad-
ditional executiveprocessing isneeded to respond toan incon-
gruenttrial; thus,ahigher interferencescoreindicatesworseper-
formance on the task. The inverse of this scorewas used in the
presentanalysessuchthat increasingscores indicatebetterper-
formance.Eachmeasurewasstandardizedbydividingthescore
by thewithin-CARDIA standard deviation and subtracting the
mean such that absolute and relativedifferences in these stan-
dardizedmeasures are comparable.
Other Covariates
Cigarette smoking behavior was evaluated during each
in-person CARDIA visit and at yearly contacts via the tele-
phone between CARDIA visits. These data were used to esti-
mate cumulative lifetime exposure to cigarettes in terms of
pack-years, with 1 pack-year of exposure equivalent to
smoking 1 pack of cigarettes per day for 1 year.8,14 We esti-
mated lifetime alcohol consumption in drink-years, defining
1 drink-year as the amount of alcohol consumed in 1 year by
a person consuming 1 drink per day (eAppendix 1 in the
Supplement).15 We estimated total lifetime episodes of
acute heavy exposure to alcohol (bingeing), defined as
reporting 5 or more drinks on 1 occasion. We estimated total
number of lifetime exposures to cocaine (including other
forms of cocaine, such as crack, powder, or freebase),
amphetamines (speed, uppers, or methamphetamines), and
heroin (eAppendix 1 in the Supplement).16,17 Educational
level was measured as the maximum educational grade
attained for each participant across reports at each visit.
Physical activity was measured with the CARDIA Physical
Association BetweenMarijuana Use and Cognitive Function in Middle Age Original Investigation Research
jamainternalmedicine.com (Reprinted) JAMA Internal Medicine March 2016 Volume 176, Number 3 353
Downloaded From:  by a UNIVERSITE DE LAUSANNE User  on 10/13/2017
Copyright 2016 American Medical Association. All rights reserved.
Activity History questionnaire, which queries the amount of
time per week spent in 13 categories of leisure, occupa-
tional, and household physical activities during the past 12
months.18 Self-reported depression was measured every 5
years starting at the year 5 visit using the Center for Epide-
miologic Studies Depression scale.19 We used cardiovascular
risk factor measurements, including blood pressure, blood
cholesterol levels (total, low-density lipoprotein, and high-
density lipoprotein cholesterol, as well as triglyceride lev-
els), fasting glucose level, and body mass index, and calcu-
lated cumulative exposures to these measurements and for
physical activity anddepression (areaunder the curve for con-
tinuous measurements [eAppendix 1 in the Supplement]).20
The number of years using antidepressant medication was
computed by adding the number of years reporting the use of
1 or more antidepressant medication (eAppendix 1 in the
Supplement). Self-reported schizophrenia was based on
self-reportedmental disease, reasons forhospitalizations, and
reasons for taking a psychoactive medication (eAppendix 1
in the Supplement). At year 2, the mirror star tracing test
was conducted to elicit reactive blood pressure. In the mir-
ror star tracing test, participants had to trace the outline of a
star from a reversed image displayed in a mirror while stay-
ing within narrow limits.21,22 Study participants were
instructed to draw stars as quickly as possible with the few-
est possible errors. If they moved out of the limits of the
star, an error was scored. Total stars completed and total
number of errors over 3 minutes were recorded. Although
initially intended as a stressor to measure blood pressure
reactivity and not as a cognitive test,21,23 some have sug-
gested that the mirror star tracing test measures aspects of
executive function.22,24
Statistical Analysis
Data analysis was performed from June 7, 1986, to August 31,
2011. We used descriptive statistics to compare participants
with different levels of exposure to marijuana at the year 25
visit.Wethendescribedunadjustedassociationsbetweenmari-
juana use (current and lifetime) and each cognitive function
measure, before and after standardization. Current and life-
time marijuana exposure were significantly associated with
each other, and their potential effects on cognitive function
were difficult to differentiate owing to colinearity and poten-
tial interactions in their effects on cognitive function. Given
our primary goal of assessing potential effects of cumulative
marijuanaexposure,weeliminated theobscuring influenceof
current marijuana use by excluding the few CARDIA partici-
pants whowere currently usingmarijuana at the year 25 visit
from our primary analyses. We used linear regression to as-
sess independent associations between years of exposure to
marijuana and cognitive function outcomes. We estimated a
sequence ofmodels: the firstmodel was unadjusted; the sec-
ondmodel controlled for the covariates used to achieve a bal-
anceof sampling inCARDIA:age, race/ethnicity, sex, studycen-
ter, and years of education. The third model additionally
controlled for covariatespotentiallyassociatedwithbothmari-
juana use and cognition: use of alcohol, cocaine, amphet-
amines, andheroin; age theparticipants started smoking ciga-
rettes; cardiovascular risk factors; physical activity; bodymass
index; depression; and type 2 diabetesmellitus at the year 25
visit. Educational level, drink-years of alcohol, physical activ-
ity, and body mass index were flexibly modeled using re-
stricted cubic splineswith 3 knots at the quartiles of their dis-
tributions. To minimize potential bias due to informative
censoring, we used inverse probability of censoring weights
(eAppendix 1 in the Supplement).25 We adjusted for the mir-
ror star tracing test score at year 2 (near baseline) tominimize
reverse causation as an explanation for any associations be-
tweenmarijuanauseand theyear25cognitive functionscores,
andwe assessed correlations betweenmirror star tracing test
scores and year 25 cognition andmarijuana use to further in-
vestigate this potential issue (eAppendix 1 and eAppendix 2
in the Supplement). Schizophrenia andpsychotropicmedica-
tionhavebeenassociatedwithbothcognitive impairment and
marijuana use and could therefore act as confounders of the
associationbetweenmarijuanauseandcognitive function.26,27
We evaluated the sensitivity of the analyses to inclusion of
self-reported schizophrenia (eAppendix 1 in the Supplement)
as a covariate in the multivariable adjusted models and by
exclusion of participants with self-reported schizophrenia.
We also tested the sensitivity of the results by inclusion of
psychoactive medications in the main multivariable model.
We also tested the association between cumulative years of
exposure to marijuana with the components of the RAVLT
(eAppendix 2 and the eFigure in the Supplement). Tests of
statistical significance were 2-tailed, with P < .05 considered
significant. All analyses were conducted using STATA, ver-
sion 13 (StataCorp LP).
Results
Of the 3499 participants reassessed at the year 25 visit, 3385
(96.7%) had data on cognitive function and 3326 (95.1%)
had complete data on all 3 cognitive outcomes. Attrition
was more common among men, black participants, those
with heavy marijuana use, tobacco smokers, and cocaine
users (eAppendix 2 in the Supplement). Most participants
(2852 [84.3%]) reported having used marijuana before or
during the 25 years of follow-up, but most had relatively
few cumulative years of exposure (Table 1).8,18,19,28-31 Total
years of marijuana exposure was significantly associated
with other participant characteristics, including race and
sex, educational level, study site, other substance use,
physical activity, body mass index, high-density lipoprotein
cholesterol and triglyceride levels, and total number of stars
completed and errors on the mirror star tracing test, and
weakly associated with depressive symptoms and antide-
pressant medication use (Table 1).
In unadjusted analyses, currentmarijuana use at the year
25visitwasassociatedwithworseverbalmemory (RAVLT)and
processing speed (Digit Symbol Substitution Test) (eTable in
theSupplement),while lifetimeexposurewas associatedwith
worse performance on all 3 measures of cognitive function
(Table2). Inpreliminaryanalyses,wefoundevidenceofanega-
tive interaction between years of marijuana use and current
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Table 1. Characteristics of 3385 ParticipantsWith Cognitive Function Test Results at the Year 25 Visit
Variable
No Marijuana Use
(n = 533)
Ever Marijuana Use, ya
P Valueb
<0.5
(n = 1505)
0.5-2.0
(n = 800)
2.0-5.0
(n = 236)
>5.0
(n = 311)
Age, mean (SD), y 49.7 (3.9) 50.1 (3.6) 50.7 (3.4) 50.1 (3.6) 49.8 (3.7) <.01
Race and sex, No. (%)c
Black women 193 (36.2) 475 (31.6) 147 (18.4) 50 (21.2) 71 (22.8)
<.01
Black men 88 (16.5) 189 (12.6) 180 (22.5) 81 (34.3) 95 (30.5)
White women 130 (24.4) 527 (35.0) 223 (27.9) 47 (19.9) 45 (14.5)
White men 122 (22.9) 314 (20.9) 250 (31.3) 58 (24.6) 100 (32.2)
College education at any visit, No. (%) 306 (57.4) 931 (61.9) 405 (50.6) 89 (37.7) 105 (33.8) <.01
Length of education, median (IQR), y 16 (14-18) 16 (14-18) 15 (12-16) 14 (13-16) 14 (12-16) <.01
Study center, No. (%)
Birmingham, AL 240 (45.0) 355 (23.6) 132 (16.5) 45 (19.1) 43 (13.8)
<.01
Chicago, IL 138 (25.9) 344 (22.9) 201 (25.1) 49 (20.8) 48 (15.4)
Minneapolis, MI 101 (18.9) 347 (23.1) 264 (33.0) 72 (30.5) 113 (36.3)
Oakland, CA 54 (10.1) 459 (30.5) 203 (25.4) 70 (29.7) 107 (34.4)
Current marijuana use, days per month,
No. (%)d
No current use 533 (100) 1483 (98.5) 743 (92.9) 153 (64.8) 81 (26.0)
1-10 0 12 (0.8) 23 (2.9) 16 (6.8) 9 (2.9)
<.0111-29 0 10 (0.7) 34 (4.3) 64 (27.1) 159 (51.1)
30 (every day) 0 0 0 3 (1.2) 62 (19.9)
Cigarette smoking, No. (%)
Never 462 (86.7) 923 (61.3) 219 (27.4) 59 (25.0) 60 (19.3)
<.01Current 17 (3.2) 162 (10.8) 199 (24.9) 78 (33.1) 124 (39.9)
Former 54 (10.1) 420 (27.9) 382 (47.8) 99 (41.9) 127 (40.8)
Age started smoking among ever cigarette
smokers, median (IQR), y
22 (17-32) 18 (15-21) 16 (15-19) 17 (15-20) 17 (15-21) <.01
Pack-years during lifetime among ever
cigarette smokers, median (IQR), No.e
2 (0-12) 5 (1-13) 9 (2-17) 9 (3-18) 10 (3-21) <.01
Current alcohol use, No. (%)f
Abstainer 362 (67.9) 682 (45.3) 310 (38.8) 84 (35.6) 92 (29.6)
<.01Light to moderate 171 (32.1) 802 (53.3) 453 (56.6) 141 (59.7) 189 (60.8)
Heavy 0 17 (1.1) 36 (4.5) 10 (4.2) 29 (9.3)
Cumulative drink-years, median (IQR)g 8 (3-17) 14 (6-26) 21 (11-37) 24 (11-48) 35 (17-68) <.01
Binge-drinking days, cumulative use, No. (%)h
Never reported bingeing 432 (81.1) 817 (54.3) 241 (30.1) 57 (24.2) 51 (16.4)
<.01≤250 d 64 (12.0) 431 (28.6) 260 (32.5) 67 (28.4) 85 (27.3)
>250 d 37 (6.9) 257 (17.1) 299 (37.4) 112 (47.5) 175 (56.3)
Current illicit drug use,i No. (%)
Cocaine, crack, speed, or metamphetamine 2 (0.4) 11 (0.7) 26 (3.3) 15 (6.4) 33 (10.6) <.01
Heroin 0 2 (0.1) 6 (0.8) 2 (0.8) 4 (1.3) <.01
Cumulative use of cocaine, crack, speed or
metamphetamine, No. (%)
Never reported using 526 (98.7) 1000 (66.4) 202 (25.3) 46 (19.5) 47 (15.1)
<.01
1-25 d 4 (0.8) 338 (22.5) 217 (27.1) 58 (24.6) 63 (20.3)
>25-250 d 1 (0.2) 132 (8.8) 253 (31.6) 77 (32.6) 109 (35.0)
>250 d 2 (0.4) 35 (2.3) 128 (16.0) 55 (23.3) 92 (29.6)
Cumulative use of heroin, No. (%)
Never reported using 528 (99.1) 1469 (97.6) 695 (86.9) 202 (85.6) 266 (85.5)
<.011-25 d 5 (0.9) 29 (1.9) 63 (7.9) 19 (8.1) 21 (6.8)
≥25 d 0 7 (0.5) 42 (5.3) 15 (6.4) 24 (7.7)
Physical activity score, median (IQR)j 233 (83-409) 267 (136-485) 309 (151-529) 263 (133-475) 322 (171-520) <.01
BMI, mean (SD) 31.5 (7.3) 30.1 (7.6) 29.8 (6.8) 30.1 (29.1) 29.5 (6.0) <.01
Cardiovascular risk factors, mean (SD)
(continued)
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use at the year 25 visit in both unadjusted (P < .001) andmul-
tivariable-adjustedmodels (P = .03) for the RAVLT, such that
pastmarijuana use appeared to be less important as a predic-
tor of verbalmemory among participantswhowere currently
using marijuana (eAppendix 2 in the Supplement). With or
without exclusion of current users, lifetime exposure to
marijuanawas associatedwith reductions in all 3measures of
cognitive function (Table 2).
In fully adjusted analyses excluding current users, life-
time exposure to marijuana remained significantly associ-
ated with worse verbal memory (RAVLT), even after exten-
siveadjustment forother factorsassociatedwithmarijuanause
andmirror star tracing scores at the year 2 visit (Table 3). The
associationwas dose dependent, with no evidence of nonlin-
earity (Figure); each additional 5 years of exposure to mari-
juanawas associatedwith0.13 lower standardizedunits in the
Table 1. Characteristics of 3385 ParticipantsWith Cognitive Function Test Results at the Year 25 Visit (continued)
Variable
No Marijuana Use
(n = 533)
Ever Marijuana Use, ya
P Valueb
<0.5
(n = 1505)
0.5-2.0
(n = 800)
2.0-5.0
(n = 236)
>5.0
(n = 311)
Blood pressure, mm Hg
Systolic 120 (17) 118 (16) 119 (16) 122 (16) 123 (16) <.01
Diastolic 75 (12) 74 (11) 75 (11) 76 (12) 77 (11) <.01
Cholesterol level, mg/dL
LDL 113 (34) 112 (32) 112 (33) 109 (32) 110 (32) .44
HDL 56 (16) 60 (18) 57 (18) 57 (20) 56 (18) <.01
Triglycerides 109 (71) 107 (79) 123 (95) 115 (68) 129 (124) <.01
Type 2 diabetes mellitus, No. (%) 77 (14.4) 204 (13.6) 114 (14.3) 26 (11.0) 33 (10.6) .41
Psychological variables
Depression, current CES-D score ≥16/30,
No. (%)k
72 (13.5) 216 (14.4) 118 (14.8) 47 (19.9) 60 (19.3) .03
Years of antidepressant medication use,
No. (%)l
Never reported using 453 (85.0) 1166 (77.5) 616 (77.0) 180 (76.3) 251 (80.7)
<.011-5 y 57 (10.7) 263 (17.5) 138 (17.3) 40 (16.9) 51 (16.4)
>5 y 22 (4.1) 76 (5.0) 46 (5.8) 16 (6.8) 9 (2.9)
Self-reported schizophreniam 0 6 (0.4) 5 (0.6) 2 (0.8) 1 (0.3) .38
Cognitive function at the year 2 visit, mirror
star tracing test score,n median (IQR)
No. of stars completed 4 (3-6) 4 (3-7) 4 (2-6) 4 (2-6) 4 (2-6) <.01
No. of errors 21 (7-48) 23 (8-48) 24 (9-53) 23 (9-49) 27 (12-54) .03
Abbreviations: BMI, bodymass index (calculated as weight in kilograms divided
by height in meters squared); CARDIA, Coronary Artery Risk Development in
Young Adults; CES-D, Center for Epidemiologic Studies Depression scale;
IQR, interquartile range; LDL, low density lipoprotein; HDL, high-density
lipoprotein.
SI conversion factors: To convert LDL and HDL tomillimoles per liter, multiply
by 0.0259; to convert triglycerides to millimoles per liter, multiply by 0.0113.
a Cumulative lifetime exposure to marijuana joints in terms of marijuana-years,
with 1 marijuana-year of exposure equivalent to 365 days usedmarijuana
(1 year × 365 days per year).8,28
bP values are from 1-way analyses of variance for age, BMI, systolic and diastolic
blood pressure, LDL cholesterol, HDL cholesterol, and triglyceride levels; from
a χ2 test for race and sex, college education, study center, income, and alcohol
use category; and from a Kruskal-Wallis nonparametric test for pack-years,
years of education, cigarettes smoked per day, drink-years, binge-drinking
days, and physical activity. All P values are 2-tailed.
c By design, the CARDIA study sampled self-identified white men, white
women, black men, and black women in roughly equal numbers for
participation in the study.29
dCategories based on the answer to the question, “During the last 30 days, on
howmany days did you usemarijuana?”
e Cumulative lifetime exposure to cigarettes in terms of pack-years, with 1
pack-year of exposure equivalent to 7300 cigarettes (1 year × 365 days per
year × 1 pack per day × 20 cigarettes per pack).8
f Categories of alcohol consumption were based on the sex-specific weekly
maximum drinking limits published by the National Institute on Alcohol Abuse
and Alcoholism (for men,14 [women7] standard drinks per week or4
[3] drinks per day).30
g Drink-years in those reporting ever drinking alcohol. A drink-year was defined
as the total amount of ethanol consumed by a person who had 1 alcoholic
drink per day for 1 year (1 drink-year = 17.24mL of ethanol per drink × 1 drink
per day × 365 days per year = 6292.6mL of ethanol).
h Binge-drinking days were defined as 5 or more drinks per episode. If bingeing
were to be constant over 25 years in 1 individual, 250 binge-drinking days
would correspond to 10 episodes of bingeing per year over 25 years.
i Current use defined as any use within the last 30 days. The number of days
using the illicit drug listed over the study duration was computed using current
exposure at each visit and replaced by lifetime exposure when the latter was
higher. Cocaine included other forms of cocaine such as crack, powder,
freebase; amphetamines included speed, uppers, andmetamphetamines.
j Physical activity measured with the CARDIA Physical Activity History
questionnaire, which queries the amount of time per week spent in 13
categories of leisure, occupational, and household physical activities over the
past 12 months.18
k Self-reported depression wasmeasured every 5 years starting at the year 5
visit by using the CES-D.19 A score of 16 or higher was used as the cutoff value
for both sexes as an indication of clinically significant depressive symptoms.31
l Antidepressant andmood stabilizing medications recorded at each clinical
visit.
mSelf-reported schizophrenia based on self-reportedmental disease, reasons
for hospitalizations, and reasons for taking a psychoactive medication.
nMirror star tracing test performed at the year 2 visit to test blood pressure
reactivity, which tests cognitive domains similar to the Stroop test; 280 of
3385 participants (8.3%) weremissing data onmirror star tracing.
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RAVLT (95%CI, –0.24 to –0.02; P = .02) (Table 3). In contrast,
adjusted models demonstrated no association of cumulative
marijuana exposure with processing speed and executive
function (Digit Symbol Substitution Test and Stroop Inter-
ference Test; Table 3). In multivariable-adjusted analyses,
total number of stars completed and errors were not associ-
ated with higher marijuana use at the year 2 visit and over
25 years of follow-up (eAppendixes 1 and 2 in the Supple-
ment). Total number of stars completed and errors were
associated with cognitive function scores at the year 25 visit
in both unadjusted and adjusted analyses (eAppendixes 1
and 2 in the Supplement). In exploratory analyses, the
attenuation of the association between marijuana exposure
and all 3 measures of cognitive function was seen mostly
after adjustment for race and sex strata and educational
level. Sensitivity analyses demonstrated no evidence of sig-
nificant interactions by race or sex (P > .10 for all tests).
Our method of identifying participants with a potential
diagnosis of schizophrenia through self-reported mental
disease, reasons for hospitalizations, and reasons for taking
psychoactive medication identified 28 participants in the
entire CARDIA cohort of 5115 (0.5%). Of those, 14 of 3385
attended the year 25 visit (0.4%) compared with 14 of 1730
not attending (0.8%) (P = .07 for those not attending the
year 25 visit). Results were virtually unchanged when
including this covariate in the main multivariable-adjusted
model and the inverse probability of censoring weights or
excluding these participants from the main analyses. Simi-
larly, inclusion of the predictor of antidepressant medica-
tion led to similar results.
Table 2. Association Between Cognitive Function and Exposure toMarijuana Among CARDIA Study Participants at Year 25
Marijuana Exposure No.
Rey Auditory Verbal
Learning–Test
No.
Digit Symbol Substitution Test
No.
Stroop Interference Testa
Raw Mean
(SD)
Standardized
Mean
Raw Mean
(SD)
Standardized
Mean
Raw Mean
(SD)
Standardized
Mean
All participants 3365 8.3 (3.7) 0.00 3370 69.9 (16) 0.00 3352 −23 (11) 0.00
Overall exposure
Never 531 8.6 (3.2) 0.09 531 70 (16) −0.02 528 −23 (12) −0.07
Past 2443 8.4 (3.2) 0.03 2448 71 (16) 0.04 2436 −22 (11) 0.03
Current 391 7.2 (3.4) −0.32 391 67 (15) −0.21 388 −24 (12) −0.08
P valueb <.001 <.001 .03
Current use (last 30 d)c
None 2974 8.5 (3.2) 0.04 2979 70 (16) 0.03 2964 −23 (11) 0.01
1-10 d 226 7.5 (3.5) −0.24 226 68 (15) −0.15 224 −23 (11) −0.05
11 to 29 d 100 7.3 (3.3) −0.31 101 68 (16) −0.13 100 −22 (10) 0.02
30 d (daily) 65 6.2 (3.4) −0.66 64 61 (13) −0.55 64 −27 (15) −0.37
P valueb <.001 <.001 .02
Lifetime exposure,
cumulatived
Never used 531 8.6 (3.2) 0.09 531 70 (16) −0.02 528 −23 (12) −0.07
1 d to <0.5
Marijuana-years
1496 8.8 (3.2) 0.14 1498 72 (16) 0.16 1493 −22 (11) 0.06
0.5 to <2
Marijuana-years
792 8.1 (3.2) −0.08 799 68 (16) −0.10 791 −23 (11) 0.00
2 to <5 Marijuana-years 236 7.5 (3.3) −0.24 233 65 (17) −0.28 234 −23 (10) −0.05
>5 Marijuana-years 310 6.9 (3.4) −0.43 309 65 (15) −0.28 306 −24 (12) −0.12
P valueb <.001 <.001 .01
Lifetime exposure,
cumulative, excluding
current userse
Never used 531 8.6 (3.2) 0.09 531 70 (16) −0.02 528 −23 (12) −0.07
1 d to <0.5
Marijuana-years
1474 8.8 (3.1) 0.15 1476 73 (16) 0.16 1472 −22 (11) 0.06
0.5 to <2
Marijuana-years
735 8.0 (3.2) −0.08 742 68 (16) −0.10 734 −23 (10) 0.02
2 to <5 Marijuana-years 153 7.5 (3.3) −0.24 150 64 (17) −0.35 151 −24 (11) −0.10
>5 Marijuana-years 81 6.9 (3.2) −0.43 80 66 (15) −0.27 79 −25 (11) −0.19
P valueb <.001 <.001 .02
Abbreviation: CARDIA, Coronary Artery Risk Development in Young Adults.
a The inverse of the Stroop score is used in the present analyses to allow
interpretation of worse cognitive function with negative standardized scores
for all 3 cognitive function tests.
bP values are from 1-way analyses of variance. All P values are 2-tailed.
c Current exposure to marijuana assessed through the question, “During the last
30 days, on howmany days did you usemarijuana?”
dCumulative exposure to marijuana expressed in marijuana-years, with 1
marijuana-year of exposure equivalent to 365 days of marijuana use.
e Current marijuana users at the year 25 visit excluded (n=391).
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Discussion
In this largecommunity-basedcohortofwhiteandblackyoung
adults followedupover 25 years,we found adose-dependent
independent association between cumulative lifetime expo-
sure tomarijuanaandworseningverbalmemory inmiddleage.
For each additional 5marijuana-years of exposure (1825 days
of use), verbal memory was 0.13 standardized units lower af-
ter full adjustment than for those who had never used mari-
juana, corresponding to amean of 1 of 2 participants remem-
bering 1word fewer from a list of 15words for every 5 years of
use. We found no significant associations of cumulative ex-
posure with executive function or processing speed.
Our findings are consistent with those of previous stud-
ies demonstrating associations between heavy exposure to
marijuana and cognitive function, but, to our knowledge, the
association with lower levels of marijuana exposure has not
previously been demonstrated.3-5,32,33 In one study, for ex-
ample, the associationwithverbalmemorywas apparent only
among those with heavy long-term use of marijuana (n=51),4
defined as use of marijuana every day or nearly every day for
more than 20 years (23.9 years of use), compared with more
recent use (10.2 years of use; n=51) or nonusers (n=33). In an-
Table 3. Association Between Cognitive Function and Cumulative Lifetime Exposure toMarijuana inMarijuana-years Among Those
Without Recent Usea
Cumulative Lifetime Exposure
in Marijuana-yearsc
Standardized Difference in Each Cognitive Function Measure (95% CI)b
Unadjusted
Model
Adjusted for Age, Race, Sex,
Educational Level, Study
Center, and With IPCWd
Additionally Adjusted
for Substance Use,
Depression, and
Cardiovascular Risk Factorse
Additionally Adjusted for
Mirror Star Tracing Test
Score at the Year 2 Visitf
Rey Auditory Verbal Learning Test
Never used marijuana 0 [Reference] 0 [Reference] 0 [Reference] 0 [Reference]
1 d to <0.5 Marijuana-years 0.06 (−0.04 to 0.16) −0.01 (−0.11 to 0.08) −0.02 (−0.12 to 0.08) −0.03 (−0.13 to 0.08)
0.5 to <2 Marijuana-years −0.17 (−0.28 to −0.06) −0.07 (−0.18 to 0.04) −0.07 (−0.21 to 0.06) −0.08 (−0.22 to 0.06)
2 to <5 Marijuana-years −0.33 (−0.51 to −0.15) −0.11 (−0.28 to 0.06) −0.09 (−0.28 to 0.09) −0.08 (−0.27 to 0.11)
>5 Marijuana-years −0.52 (−0.75 to −0.29) −0.27 (−0.49 to −0.05) −0.31 (−0.54 to −0.07) −0.25 (−0.50 to −0.01)
P value for trend <.001 .007 .01 .04
For every 5 marijuana-years −0.34 (−0.45 to −0.24) −0.15 (−0.24 to −0.05) −0.15 (−0.25 to −0.04) −0.13 (−0.24 to −0.02)
P value <.001 .002 .005 .02
Digit Symbol Substitution Test
Never used marijuana 0 [Reference] 0 [Reference] 0 [Reference] 0 [Reference]
1 d to <0.5 Marijuana-years 0.17 (0.07 to 0.27) 0.03 (−0.06 to 0.12) 0.06 (−0.04 to 0.16) 0.06 (−0.04 to 0.16)
0.5 to <2 Marijuana-years −0.08 (−0.19 to 0.03) −0.03 (−0.13 to 0.07) 0.07 (−0.06 to 0.19) 0.05 (−0.08 to 0.18)
2 to <5 Marijuana-years −0.33 (−0.51 to −0.16) −0.12 (−0.28 to 0.04) −0.03 (−0.21 to 0.15) −0.02 (−0.20 to 0.17)
>5 Marijuana-years −0.25 (−0.48 to −0.02) −0.04 (−0.24 to 0.15) 0.12 (−0.08 to 0.33) 0.13 (−0.09 to 0.34)
P value for trend <.001 .26 .57 .45
For every 5 marijuana-years −0.31 (−0.41 to −0.20) −0.08 (−0.17 to 0.01) −0.01 (−0.10 to 0.08) −0.03 (−0.12 to 0.07)
P value <.001 .08 .77 .56
Stroop Interference Testg
Never used marijuana 0 [Reference] 0 [Reference] 0 [Reference] 0 [Reference]
1 d to <0.5 Marijuana-years 0.12 (0.02 to 0.22) 0.06 (−0.05 to 0.17) 0.05 (−0.06 to 0.17) 0.05 (−0.07 to 0.17)
0.5 to <2 Marijuana-years 0.09 (−0.02 to 0.20) 0.10 (−0.02 to 0.23) 0.13 (−0.04 to 0.29) 0.11 (−0.06 to 0.27)
2 to <5 Marijuana-years −0.03 (−0.21 to 0.15) 0.10 (−0.09 to 0.29) 0.08 (−0.13 to 0.29) 0.10 (−0.11 to 0.31)
>5 Marijuana-years −0.12 (−0.36 to 0.11) −0.08 (−0.32 to 0.17) −0.02 (−0.30 to 0.24) −0.09 (−0.37 to 0.20)
P value for trend .12 .71 .92 .71
For every 5 marijuana-years −0.09 (−0.20 to 0.01) −0.02 (−0.12 to 0.09) −0.01 (−0.13 to 0.10) −0.04 (−0.16 to 0.08)
P value .08 .80 .80 .51
Abbreviation: IPCW, inverse probability of censoring weight.
a Cumulative exposure to marijuana expressed in marijuana-years, with
1 marijuana-year of exposure equivalent to 365 days of marijuana use. Current
marijuana users within the 30 days prior of the year 25 visit excluded (n=392).
b Cumulative exposure to marijuana use. Negative standardized scores indicate
worse cognitive function.
c Years of marijuana exposure wasmodeled first as a 5-level categorical
predictor and then as a continuous linear predictor, per 5 marijuana-years
(separate models).
dAdjusted for age, race/ethnicity, sex, study site, and years of education.
Analyses weighted by the inverse probability of censoring to address potential
bias by informative censoring.
e Additionally adjusted for cumulative and current exposure to licit and illicit
substances and other covariates.
f Additionally adjusted for total number of stars completed and errors made
drawing the stars. Participants with missing data onmirror star tracing test
excluded (n=280).
g The inverse of the Stroop score was used in the present analyses to allow
interpretation of worse cognitive function with negative standardized scores
for all 3 cognitive function tests.
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other study, investigatorsused38yearsof follow-updata from
1037 participants in a birth cohort in New Zealand and found
that persistent regular cannabis use (4daysperweekormore)
was associatedwith neuropsychological decline, while those
whoreportednonregularuse (508 [50.6%]of the total) showed
no decline in IQ or neuropsychological performance.5 Simi-
larly, a longitudinal studywith 10yearsof follow-up foundevi-
dence of cognitive decline with heavy marijuana use,33 but
those who stopped usingmarijuana during follow-up did not
showadecline in IQscore. Incontrast,withmoredetailedmea-
surement of lifetime marijuana exposure in a larger sample,
we were able to detect a negative association at lower levels
of cumulativeuse and amongpersonswith remotepast expo-
sure to marijuana.
The extent of association between worse verbal memory
and cumulative marijuana use is of uncertain clinical signifi-
cance. In the context of cognitive decline after stroke, Levine
et al34 used a 0.5-SD cutoff for defining a clinically meaning-
ful decline in global cognition. The point estimate for verbal
memory in our study for those with 5 marijuana-years of ex-
posure (0.13 standardized units; 95%CI, −0.24 to −0.02) is of
lessermagnitude than thedecline found in thestudybyLevine
et al and the confidence interval excludes the 0.5-SD cutoff.
However, participantswith up to 10marijuana-years of expo-
suremight have a significant decline in verbal memory given
the lowerboundof the95%CI. Similarly,participantswithcur-
rent dailymarijuana use in themonth before the year 25 visit
might have a clinically significant decrease in verbalmemory
and othermeasures of cognitive function (eAppendix 2 in the
Supplement).
Themechanismbywhichmarijuanaexposuremightaffect
verbal memory is unclear but might be explained by the po-
tential effect of tetrahydrocannabinol on theway inwhich in-
formation is processed in the hippocampus.35 Marijuana use
has been associatedwith functional changes in the activation
of brain regions involved in associative learning,36 particu-
larly in theparahippocampal regions and thedorsolateral pre-
frontal cortex.36-38 Some have found suggestions of lower
hippocampalandamygdalavolumes in thosewithheavy, long-
term use ofmarijuana (>5 joints daily for >10 years),39 as well
as alterations in the cerebellum, frontal cortex,36 and medial
temporal cortex,38 althoughother researcherswere unable to
confirm these findings.35,40 Numerous issues related to the
methods, such as variation in imaging techniques and inmea-
surement of exposures, dose-threshold effects, and small
sample sizes, limit the possibility for drawing significant con-
clusions on the published findings.36,38
Our study has limitations. We constructed a marijuana
exposure measurement from self-reported information col-
lected prospectively and periodically over 25 years, but self-
report is not always reliable,41 measurements were infre-
quent, andageof exposure, especiallyduringadolescenceand
young adulthood, was not queried. However, even if impre-
cise, the repeated question over the 25 years was prospec-
tively obtainedandallowedus todemonstrate apotential del-
eterious association, one that is not easily studied without a
large,well-characterizedcohortwith long-termfollow-up, such
as the CARDIA study. Another limitation is the availability of
Figure. Associations Between Lifetime Exposure toMarijuana
and Cognitive Function
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Rey auditory verbal testA
Years of marijuana usemodeled flexibly and current marijuana users at the year
25 visit excluded (n = 392). Results are adjusted for age, race/ethnicity, sex,
study site, educational level, cigarette smoking, alcohol use, illicit drug use,
cardiovascular risk factors, depression, mirror star tracing test score at the year
2 visit, and differential likelihood of follow-up (see theMethods section). All test
results are standardized, such that a 1-U negative deviation indicates 1-SD worse
cognitive function than themean. Histograms describe the distribution of
marijuana-years in participants in the Coronary Artery Risk Development in
Young Adults study with any exposure to marijuana by presenting the
frequency of participants in each considered interval. The inverse of the Stroop
score is used in the present analyses to allow interpretation of worse cognitive
function with negative standardized scores for all 3 cognitive function tests.
DSST indicates Digit Symbol Substitution Test; RAVLT, Rey Auditory Verbal
Learning Test.
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cognitive functionmeasurements at only 1 time point, which
limits our ability to pinpoint when a change in the outcome
might have occurred and associate it in timewith a change in
exposure. We found no significant change in the measure of
associationbetweencumulativemarijuanaexposureandmea-
suresofcognitive functionafter inclusionof themirrorstar trac-
ing tests score measured early in life (year 2 visit). Even with
this adjustment, we cannot rule out reverse causation as an
explanation for our results.5While some have suggested that
the mirror star tracing test measures aspects of executive
function,22,24 to our knowledge, no study has compared the
cognitive function domainsmeasured in themirror star trac-
ing test and thosemeasured in the other tests used at the year
25 visit. Factors significantly associated with marijuana use
could confound the association between marijuana and cog-
nitive function.TheNewZealandstudy, for example, hasbeen
criticized for lack of adequate control of socioeconomic
status,42eventhoughadditionalanalyseshaveshownthatcon-
trolling for socioeconomic status did not attenuate the asso-
ciationbetweensustaineddailymarijuanauseandworse IQ.43
In our study, the observed associationswere substantially at-
tenuated by control for core demographic variables, includ-
ing educational level, race, and sex. However, adjustment for
a host of additional behavioral, psychosocial, and cardiovas-
cular risk factors available, including self-reportedschizophre-
niaandpsychoactivemedication,didnot further attenuate the
estimates.
Conclusions
We found past exposure to marijuana use to be significantly
associated with worse verbal memory in middle age. Future
studieswithmultiple assessmentsof cognition,brain imaging,
and other functional outcomes should further explore these
associations and their potential clinical and public health im-
plications. In the meantime, with recent changes in legisla-
tionandthepotential for increasingmarijuanause intheUnited
States,44 continuing to warn potential users about the pos-
sible harm from exposure to marijuana seems reasonable.45
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